This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Prescribing Information for NGENLA▼(somatrogon) can be found here. Prescribing Information for Genotropin (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page.
|
Product Name |
PIP Code |
|---|---|
|
Ngenla 24mg solution for injection in pre filled pen (GB) |
540-0098 |
|
Ngenla 60mg solution for injection in pre filled pen (GB) |
540-0080 |
|
Ngenla 24mg solution for injection in pre filled pen (NI) |
520-2551 |
|
Ngenla 60mg solution for injection in pre filled pen (NI) |
520-2569 |
The recommended dose is 0.66mg/kg bodyweight administered once weekly by subcutaneous injection.
|
Device type |
Dose setting increments |
Suggested dose |
|---|---|---|
|
24mg solution for |
0.2mg |
Suggested for doses less than 12mg (bodyweight <18kg). |
|
60mg solution for |
0.5mg |
Suggested for doses of 12mg and above (bodyweight 18kg or over). |
The Endocrine Helpline can support patients by placing an order for consumable items such as needles, sharps bins and patient literature.
The service can also support clinicians in ordering starter kits for patients starting on NGENLA.
Pfizer will provide a box of needles as standard within the patient starter box:
- BD Micro-Fine Ultra 4mm 32G needles (quantity 100)
For resupply, or to order additional or different needles at no cost, the patient/caregiver or Healthcare Professional can contact the Endocrine Helpline on 0800 521249 or [email protected]
Find out information about the starter kits available to patients starting treatment with NGENLA.
Access the document to support initiation of NGENLA.
References:
Learn more about how NGENLA is stored, recommended dosing, and adminstration.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021